您的位置: 首页 > 2025年8月 第56卷 第8期 > 文字全文
2023年7月 第38卷 第7期11
目录

构建基于 MIMIC-IV 数据库的主动脉夹层 B 型患者急性期死亡风险列线图预测模型:一项回顾性分析

Development of a nomogram predictive model for acute mortality risk in patients with type B aortic dissection based on the MIMIC-IV database:A retrospective analysis

来源期刊: 广州医药 | 1134-1144 发布时间:2025-08-20 收稿时间:2025/9/25 11:36:32 阅读量:45
作者:
关键词:
列线图主动脉夹层B型重症监护医学信息数据库预测模型死亡风险
DOI:
10. 20223 / j. cnki. 1000-8535. 2025. 08. 018
收稿时间:
2024-05-17 
修订日期:
 
接收日期:
 
引用总数:
0  
       目的   构建并验证主动脉夹层B型(TBAD)患者急性期预后的列线图预测模型,帮助临床医生在急性期内更准确地评估TBAD患者的死亡风险,并制定更合适的治疗策略。方法   回顾性分析从重症监护医学信息数据库v2.2 中提取的399例 TBAD患者的人口学资料和临床资料,结局为TBAD患者急性期(≤14 d)内死亡。先采用最小绝对收缩选择算法回归筛选特征变量,再采用多因素分析确定独立预后因素,并据此构建预测模型。通过受试者工作特征曲线、校准曲线、决策曲线分析(DCA)评价列线图预测模型的性能和临床适用性。结果  APS Ⅲ评分、二氧化碳总量、红细胞分布宽度为TBAD患者14 d内死亡的独立预测因素。列线图预测模型在内部验证中的受试者工作特征曲线下面积为0.776(95% CI0.691 ~ 0.860),Hosmer-Lemeshow 检验P=0.604,校准曲线和标准曲线高度重合,表明该模型具有良好的区分度和校准度。同时,DCA曲线显示,预测模型在大部分的阈值概率范围内提供了显著的净收益。结论   本研究基于APS Ⅲ评分、二氧化碳总量、红细胞分布宽度构建的列线图预测模型可以较准确地预测TBAD患者14 d内的死亡风险,有助于临床医生制定更合适的个体化治疗策略。
       Objective  To develop and verify a nomogram for predicting acute phase outcomes in patients with type B aortic dissection(TBAD),enabling clinicians to more precisely evaluate mortality  risk in TBAD patients during the acute stage and to devise better treatment plans.Methods  This retrospective study analyzed demographic and clinical data of 399 TBAD patients from the Medical Information Mart for Intensive Care IV v2.2,focusing on mortality within 14 days of the acute phase in TBAD patients.Initially,the Least Absolute Shrinkage and Selection Operator regression was employed for feature variable selection,and then multivariate analysis was used to identify independent prognostic factors for constructing the predictive model.The nomogram predictive model’s effectiveness and clinical applicability were assessed via the Receiver Operating Characteristic curve,calibration curve,and Decision Curve Analysis(DCA).Results  Acute Physidogy Score Ⅲ score,total carbon dioxide,and red blood cell distribution width emerged as independent predictors of 14-day mortality in TBAD patients.The internal validation of the nomogram predictive model showed an area under the curve of 0.776(95%CI:0.691-0.860),with a Hosmer-Lemeshow test P-value of 0.604.The close alignment of the calibration and standard curves suggested the model’s strong discriminative power and calibration.Furthermore,the DCA curve  revealed that the predictive model offered substantial net benefits within a wide  range of threshold probabilities.Conclusions  This study's nomogram,developed using APS Ⅲ score,total carbon dioxide,and  red blood cell distribution width,accurately predicts the 14-day mortality risk in TBAD patients,assisting clinicians in creating better personalized treatment plans.
       主动脉夹层(aortic dissection,AD)是一种十分凶险的主动脉疾病,通常是由于主动脉内膜撕裂引起,根据Stanford分型分为A型主动脉夹层(type A aortic dissection,TAAD)、B型主动脉夹层(type B aortic dissection,TBAD)。TAAD破口位于升主动脉或主动脉弓,发病后每小时死亡率增加1%~2%,总体累计死亡率高达27.4%,不进行手术的患者死亡率甚至高达58%[1],因此TAAD通常需要紧急手术。TBAD破口位于降主动脉,按照发病时间又可分为急性期(≤14 d)、亚急性期(15~90 d)及慢性期(>90 d)[2],其凶险程度较TAAD低,据统计TBAD患者的30 d死亡率为13.3%[3]
       既往有研究指出,对于不具有主动脉破裂、严重灌注不良等高危因素的非复杂型 TBAD推荐以药物治疗控制患者血压、心率为首选[4–6]。随着腔内介入治疗技术的发展,胸主动脉腔内修复术(thoracic endovascular aortic repair,TEVAR)以其创伤小、恢复快、术后并发症发生率低、患者生存率高等优点被广泛应用[7-8]。但关于TEVAR的最佳手术时机目前仍存在较大争议,一些研究表明,在亚急性期进行TEVAR手术可能在治疗效果和并发症发生率方面表现更优[9]。然而其他研究则指出,急性期手术的疗效和安全性并不逊于亚急性期,并且可能提高术后主动脉重塑率[10]因此,对于TBAD的治疗,早期死亡风险的准确预测对于指导治疗决策至关重要。目前,对于TBAD患者的风险评估主要依赖于临床表现和影像学特征。然而,这些方法在预测短期死亡风险方面存在局限性,尤其是在急性期内的14 d死亡风险[11]。近年来,越来越多的研究表明,预测模型在临床决策中发挥着重要作用,特别是在早期疾病风险识别、疾病复发风险评估、治疗后不良反应监测以及术后复发预防等方面取得了显著进展[12–17]。因此,构建一个基于大型数据库的预测模型,如重症监护医学信息数据库( Medical Information Mart for Intensive Care Ⅳ,MIMIC-Ⅳ)数据库,对于改善TBAD患者的早期风险评估和管理具有重要意义。
       本研究旨在利用MIMIC-Ⅳ数据库中提取的数据,构建并验证一个针对TBAD患者14 d内死亡的列线图预测模型。该模型的意义在于提供一个可靠的风险评估工具,以帮助临床医生在急性期内更准确地评估TBAD患者的死亡风险,并据此制定更合适的治疗策略。

1  材料与方法

1.1  数据来源

       数据来源于MIMIC-Ⅳ v2.2,该数据库是一个开放型公共数据库,收集了2008—2019年麻省理工贝斯以色列迪康医学中心(Intensive Care Unit,ICU)收治的超过19万名患者、45万次住院记录的真实临床医疗数据。该数据库中所有患者信息均通过隐匿化处理后储存,并通过了贝斯以色列女执事医疗中心和麻省理工学院机构伦理审查委员会的批准。提取数据人员参与培训,获得使用和下载数据库的权限证书即可进行数据提取,而无须患者知情同意。本研究采用PostgreSQL软件登录MIMIC-Ⅳ数据库,并用结构化查询语言代码获取所有研究数据。数据库授权证书编码(ID:57659886)。

1.2  研究对象

       回顾性分析ICU的TBAD患者。纳入标准:(1)MIMIC-Ⅳ v2.2数据库中所有TBAD患者,TBAD的诊断符合国际疾病统计分类(The International  Statistical  Classification  of Diseases Code,ICD)的诊断代码;(2)首次收入ICU;(3)年龄>18岁。排除标准:(1)既往已行主动脉夹层手术患者(包括外科开放手术及腔内介入手术);(2)重复收入ICU患者;(3)关键数据缺失患者。最终有399例符合纳排标准的TBAD患者纳入本研究。本研究的主要结局指标是14 d内死亡。

1.3  数据提取

       使用结构化查询语言(structured   1uery language,SQL)在 PostgreSQL 14.0软件上从MIMIC-Ⅳ v2.2数据库中提取TBAD患者相关数据,提取的临床数据,包括人口学特征、生命体征、并发症、实验室检查结果、疾病严重程度评分及患者预后信息。人口学特征包括年龄、性别、身高、体质量,并计算(body mass index,BMI);生命体征包括心率(heart rate,HR)、无创收缩压(non-invasive systolic blood pressure,NIBP-SBP)、无创舒张压(non-invasive  diastolic  blood pressure,NIBP-DBP)、无创平均动脉压(non-invasive mean arterial pressure,NIBP-MAP)、有创收缩压(invasive systolic blood pressure,IBP-SBP)、有创舒张压(invasive  diastolic blood Pressure,IBP-DBP)、有创平均动脉压(invasive mean arterial pressure,IBP-MAP)、呼吸频率(respiratory rate,RR)、外周血氧饱和度(peripheral oxygen saturation,SpO2);合并症包括糖尿病、心肌梗死、充血性心力衰竭、慢性肺部疾病,轻、中重度肝病、偏瘫等,并计算查尔森共病指数(charlson comorbidity index,CCI);实验室检查包括白细胞(w hite  bloo d Cell,WBC)计数、红细胞(red blood cell,RBC)计数、血小板(platelet,PLT)计数、血红蛋白(hemoglobin,HGB)、红细胞分布宽度(red cell distribution width,RDW)、血细胞比容(hematocrit,HCT)、血清钠(serum sodium,Na+ )、血清钾(serum potassium,K+ )、总钙(total calcium,TCA)、氯化物(chloride,CL- )、血糖(blood glucose,BG)、阴离子间隙(anion gap,AG)(阴离子间隙=[Na+ ]-([Cl- ]+[HCO3 -]))、pH值、二氧化碳分压(partial pressure of carbon dioxide,PCO2)、氧分压(partial pressure of oxygen,PO2)、二氧化碳总量(total carbon dioxide,TCO2)、血乳酸(blood lactate,Lac)、游离钙(ionized calcium,Ca2+)、凝血酶原时间(prothrombin time,PT)、部分凝血活酶时间(activated partial thromboplastin time,APTT)、凝血酶原时间国际比值(international normalized ratio,INR)、血尿素氮(blood  urea nitrogen,BUN)、血肌酐(serum creatinine,Cr);疾病严重程度评分包括SOFA(Sequential Organ Failure Assessment)评分、APS III(Acute Physiology Score III)评分、SIRS(Systemic Inflammatory Response Syndrome)评分、SAPS II(Simplified Acute Physiology Score II)评分、OASIS(Oxford Acute Severity of Illness)评分;预后信息包括患者是否死亡和患者生存时间,14 d内死亡患者为死亡组,生存时间超过14 d者为存活组。

1.4  数据处理

       为保护隐私,在MIMIC-Ⅳ数据库中对于89岁以上的患者将年龄统一替换为300岁,而这部分患者的年龄中位数为91.4岁,因此我们采用中位年龄91.4岁来代替300岁。实验室指标采用患者首次入院的初始数值,而生命体征则使用进入ICU 24 h内的平均值。异常值处理:对数据进行上下 1% 缩尾处理,即小于百分位数1%的数替换为百分位数1%数值,大于百分位数99%的数替换为百分位数99%数值。缺失值处理:对缺失率<20%的变量采用多重插补法填补。

1.5  统计学分析

       采用SPSS 26.0软件和R语言进行数据处理和统计分析。具体而言,使用R语言中的“glmnet”包来构建最小绝对收缩选择算法(Least Absolute Shrinkage And Selection Operator,LASSO)模型,“glm”包进行多因素Logistic回归分析。此外,“rms”包用于绘制列线图和校准曲线,“ggROC”包用于绘制ROC曲线,而“rmda”包用于绘制临床决策曲线(Decision Curve Analysis,DCA)曲线。
       数据处理方面,在SPSS26.0软件中对计量资料进行了正态分布检验。对于符合正态分布的数据,采用表示,并使用独立样本t检验进行两组间的比较。对于不符合正态分布的数据,采用中位数和四分位间距表示,并使用两独立样本的非参数检验(Mann-Whitney U检验)进行比较。计数资料则以百分率表示,两组间比较采用检验或Fisher确切概率法。
       在统计建模方面,首先采用LASSO进行变量选择,并通过10倍交叉验证确定最佳的lambda.1se值。随后,将LASSO回归筛选出的变量纳入多因素Logistic回归分析,再采用向后法筛选出与TBAD患者14 d内死亡相关的预测因素,以P<0.05为差异有统计学意义。此外,还利用R语言软件构建了预测TBAD患者14 d内死亡的列线图模型,并通过Bootstrap方法重复抽样1 000次对模型进行内部验证。为了评估预测模型的区分度和准确度,分别绘制了受试者工作特征(Receiver Operating Characteristic,ROC)曲线和校准曲线,并进行了Hosmer-Lemeshow拟合优度检验。最后,绘制了预测模型的DCA,以评估在临床决策中使用该模型的净获益。

2  结 果

2.1  基线特征

       根据纳排标准,最终共有399例患者纳入本研究。根据14 d内是否死亡,分为死亡组(40例)和存活组(359例),14 d内死亡率为10.03%,中位年龄为70岁。
       患者的人口学特征、生命体征、并发疾病、实验室检查结果、疾病严重程度评分见表1。

表1   死亡组和存活组的人口学特征和临床特征比较   [M (Q1,Q3)]

变量

总计(n = 399)

存活组(n = 359)

死亡组(n = 40)

P

统计量

性别[n (%)]

 

 

 

0.303

1.06

234 (58.65)

207 (57.66)

27 (67.50)

 

 

165 (41.35)

152 (4234)

13 (32.50)

 

 

年龄/

70.00(58.00,80.00)

69.00(58.00, 80.00)

72.50(58.00, 84.00)

0.222

-1.22

SOFA/

4.00 (2.00, 8.00)

4.00 (2.00, 8.00)

9.00 (4.00, 11.25)

< 0.001

-4.00

APSIII/

39.00 (30.00, 50.50)

38.00 (29.50, 48.00)

55.00 (45.50, 73.00)

< 0.001

-6.00

SIRS/

2.00(2.00, 3.00)

2.00(1.00, 3.00)

3.00(2.00, 3.00)

0.009

-2.615

SAPSII/

36.00 (30.00, 45.00)

35.00 (29.00, 44.00)

47.50 (41.25, 56.25)

< 0.001

-4.73

OASIS/

31.00 (26.00, 37.00)

31.00 (26.00, 37.00)

37.50 (33.00, 42.25)

< 0.001

-4.10

CCI

5.00 (3.00, 6.00)

5.00 (3.00, 6.00)

6.00 (4.00, 7.00)

0.124

-1.54

BMI/(kg/m2

28.30 (24.74, 32.85)

28.27 (24.76, 32.68)

28.79 (24.54, 34.04)

0.578

-0.56

WBC/(×109 L)

10.20 (8.05, 12.90)

10.10 (8.00, 12.97)

10.55 (8.64, 11.36)

0.955

-0.57

RBC/×1012/L

3.45 (3.06, 3.92)

3.48 (3.09, 3.93)

3.17 (2.93, 3.60)

0.024

-2.26

PLT/×109 /L

160.50 (120.91, 203.50)

165.00 (124.50, 206.00)

123.88 (102.84, 160.52)

< 0.001

-3.59

HGB/ g/dL

10.48 (9.40, 11.80)

10.50 (9.43, 11.80)

9.60 (8.82, 10.99)

0.019

-2.34

RDW/ %

14.15 (13.50, 15.02)

14.10 (13.48, 14.96)

14.90 (14.16, 15.74)

0.006

-2.77

HCT Median/%

31.05 (27.62, 35.52)

31.10 (27.78, 35.55)

29.69 (26.09, 34.38)

0.045

-2.00

Na+/(mEq/L

139.50 (137.00, 142.00)

139.37 (137.00, 141.58)

140.80 (138.00, 143.00)

0.153

-1.43

K+/(mEq/L

4.20 (3.86, 4.50)

4.18 (3.85, 4.45)

4.40 (4.15, 4.82)

0.002

-3.04

TCA/( mEq/L

8.50 (8.10, 8.90)

8.50 (8.10, 8.90)

8.31 (7.59, 9.15)

0.459

-0.74

Cl-/( mEq/L

105.33 (102.59, 108.47)

105.33 (102.50, 108.42)

105.59 (103.50, 109.19)

0.397

-0.85

BG/( mEq/L

124.00 (109.50, 146.50)

122.00 (108.50, 144.00)

142.50 (124.38, 165.92)

< 0.001

-3.70

AG/( mEq/L

13.17 (11.50, 15.05)

13.00 (11.33, 15.00)

15.05 (12.46, 19.00)

< 0.001

-3.68

pH

7.38 (7.34, 7.41)

7.38 (7.34, 7.42)

7.31 (7.27, 7.35)

< 0.001

-5.49

PCO2/ mmHg

40.79 (37.07, 44.12)

40.79 (37.26, 44.03)

40.62 (36.00, 45.3)

0.756

-0.31

PCO2/ mmHg

176.43 (101.55, 230.49)

181.00 (101.05, 234.45)

154.30 (106.75, 189.22)

0.197

-1.29

TCO2

24.50 (22.82, 26.38)

24.60 (23.00, 26.64)

21.48 (18.89, 24.64)

< 0.001

-4.53

Lac/(mmol/L

2.40 (1.40, 3.61)

2.26 (1.40, 3.27)

3.99 (2.31, 6.03)

< 0.001

-4.30

Ca2+/(mg/L

1.13 (1.10, 1.18)

1.13 (1.10, 1.18)

1.13 (1.05, 1.17)

0.318

-1.00

PT/s

14.43 (12.60, 16.42)

14.37 (12.60, 16.19)

15.67 (13.29, 19.68)

0.013

-2.49

APPT/s

34.67 (28.80, 44.56)

34.18 (28.69, 43.64)

38.51 (33.25, 56.47)

0.02

-2.34

INR

1.30 (1.15, 1.50)

1.30 (1.15, 1.47)

1.44 (1.20, 1.81)

0.009

-2.62

BUN/(mg/dL

18.67 (14.00, 24.00)

18.00 (14.00, 23.67)

21.09 (18.59, 27.54)

0.009

-2.61

Cr/(mg/dL

1.05 (0.78, 1.44)

1.03 (0.76, 1.40)

1.33 (1.00, 1.73)

0.002

-3.50

HR/(次/min

76.88 (69.42, 86.72)

76.63 (68.94, 86.37)

78.12 (73.09, 89.02)

0.057

-1.90

NIBP-SBP/mmHg

115.38 (106.52, 125.00)

115.27 (107.04, 125.00)

115.57 (100.96, 124.40)

0.701

-0.39

NIBP-DBP/mmHg

62.43 (55.68, 71.00)

62.22 (55.56, 70.69)

67.30 (56.85, 75.86)

0.152

-1.44

NIBP-MAP/mmHg

75.39 (68.45, 83.65)

75 (68.24, 83.59)

76.04 (70.16, 85.99)

0.373

-0.89

IBP-SBP/mmHg

114.27 (107.80, 124.52)

114.17 (107.97, 124.28)

115.53 (106.24, 129.40)

0.887

-0.14

IBP-DBP/mmHg

57.95 (52.18, 64.36)

57.80 (52.14, 64.10)

61.39 (53.4, 71.28)

0.084

-1.73

IBP-MAP/mmHg

75.95 (69.93, 81.79)

75.82 (70.04, 81.15)

78.26 (69.28, 86.28)

0.201

-1.28

RR/(次/min

17.89 (15.90, 19.74)

17.75 (15.77, 19.45)

19.05 (17.15, 20.91)

0.009

-2.61

SpO2/ %

96.83 (95.42, 98.05)

96.71 (95.41, 97.95)

97.30 (95.75, 98.85)

0.204

-1.27

 

2.2  变量筛选

       采用LASSO回归从患者收集的41个变量特征中筛选出4个系数非零的变量,当调节参数为lambda. 1se(λ=0.068)时,初步筛选的候选预测因子包括APSIII评分、二氧化碳总量、阴离子间隙及红细胞分布宽度(图1)。对以上4个变量进行共线性分析,所有变量的方差膨胀因子(variance inflation factor,VIF)均小于10,说明不存在共线性(表2)。
20250925143524_3200_thumb.png
图 1  LASSO 回归筛选最佳匹配因子
       注:图1a为LASSO回归的系数路径图,展示了各个变量的回归系数随log(λ)变化的情况,随着λ的增加,部分变量的系数收缩至零,通过交叉验证筛选出具有非零系数的特征变量。图1b显示通过10折交叉验证选择最佳λ值时的均方误差(Mean-Squared ErrorMSE)变化曲线,红色虚线为MSE均值,灰色竖线为标准误,虚线标示了两个关键λ值:λ_min对应最小MSE,λ_1se对应1个标准误内的最大λ值,依据λ_1se作为标准筛选出最佳匹配因子。

表2  LASSO 回归筛选特征变量后的共线性分析

变量

VIF

APSIII评分

1.04

二氧化碳总量

1.04

阴离子间隙

1.40

红细胞分布宽度

1.00


       随后将选定的4个变量特征纳入多因素Logistc回归分析中,选择向前法,结果表明APSIII评分、二氧化碳总量、红细胞分布宽度这3个变量为TBAD患者14 d内死亡的独立影响因素(P<0.05)。根据β值与OR值可判定APSIII评分、红细胞分布宽度为危险因素,二氧化碳总量为保护性因素。见表3。

表3   多因素 Logisitic 回归分析结果

变量

β

SE

OR( 95%CI )

P

截距

-2.036

2.280

0.130 (0.001~12.71)

0.372

APSIII评分

0.033

0.010

1.033 (1.015~1.052)

<0.001

二氧化碳总量

-0.241

0.061

0.785 (0.691~0.881)

<0.001

红细胞分布宽度

0.265

0.115

1.303 (1.034~1.629)

0.021

 

2.3  列线图预测模型的构建与验证

       将多因素Logistic分析中的独立影响因素构建TBAD患者14 d内死亡的列线图模型,见图2。列线图的应用如下:根据列线图,得出个体每个预测指标对应的分数值(points),得出各分数和的总分(total points)后,与总分相对应的预测概率为TBAD患者14 d内死亡的概率。
20250925143811_7829.png
图 2    预测 TBAD 患者 14 d 内死亡风险的列线图
       列线图预测模型的AUC值为0.787(95%CI0.702~0.871),并通过Bootstrapping 1 000次得出的曲线下面积(area under the curve,AUC)值为0.776(95%CI:0.691~0.860),表明对模型具有良好的区分度(图3、4)。本研究中所构建的列线图预测模型的校准曲线与Bootstrapping 1000次得到的校准曲线显示出良好的一致性(图5),表明列线图预测概率与实际观测概率的一致性程度较高。此外,Hosmer–Lemeshow 检验 P=0.604,表明该模型具有良好的拟合度。
20250925144054_3297.png
图 3    基于 APS Ⅲ、TCO2、RDW 预测 TBAD 患者 14 d 内死亡的 ROC 曲线图

20250925144216_7888.png

图 4   基于 1000 次 Bootstrap 抽样的 ROC 曲线图
        注:红色线为模型的表观ROC曲线(Apparent ROC),灰色线表示通过1 000次Bootstrap抽样得到的ROC曲线,展示了模型预测性能的稳定性和内部验证结果。
20250925144353_1060.png
图 5   校准曲线
        注:展示了模型预测概率与实际概率之间的校准情况。实线代表理想的校准曲线(Ideal),虚线表示逻辑回归校准(Logistic Calibration),点划线为非参数校准(Nonparametric Calibration),通过该图可以评估模型的预测概率与实际结局的匹配度。

       最后,使用DCA评估该模型在临床应用中的净效益(图6)。DCA的结果表明,与两种极端的临床场景(应用模型后所有患者均接受治疗或均未接受治疗)相比,当个体的阈值概率在0.05~1.00之间时,该列线图预测模型具有良好的临床效益。

20250925144505_4929.png
图 6   列线图的 DCA 曲线
        注:展示了不同阈值概率下,基于列线图模型(Nomogram)、全治疗(All)和不治疗(None)策略的净收益情况。红色曲线表示基于列线图的预测模型,粗灰线表示全治疗策略,细灰线表示不治疗策略。DCA曲线显示,列线图模型在较宽的阈值概率范围(0.05至1.00)提供了较高的净收益,表明其在临床应用中的潜在价值。

3  讨 论

       TBAD是一种严重的心血管疾病,其特征是主动脉远端(左锁骨下动脉远端)发生夹层,而升主动脉和主动脉弓不受影响。TBAD根据发病时间和并发症的存在分为复杂型和非复杂型,其中复杂型TBAD(co-TBAD)患者的死亡率高于非复杂型TBAD(un-TBAD)[18]。急性TBAD的住院死亡率仍然高达11%~13%左右,这表明需要更精确的风险评估和治疗策略[3,19]。在本研究中,TBAD 患者14 d内的死亡率为10.03%,与其他研究中的死亡率近似。
       本研究发现,APSIII评分和RDW是TBAD 患者14 d内死亡的独立危险因素。APSIII评分作为一个广泛应用于重症医学领域的严重程度评分系统,其在预测不同类型重症患者的死亡风险方面已被广泛验证。目前尚没有直接针对TBAD患者的APSIII评分相关研究,但在其他严重疾病中,APSIII评分已被证明是预测病情严重程度和死亡风险的有效指标。Quintana等[20]的研究表明,APSIII评分能有效预测慢性阻塞性肺疾病急性加重患者的短期死亡风险。在Pan等[21]研究中发现,APSIII评分与急性胰腺炎患者的30 d死亡率密切相关,在另外一项研究中比较了SOFA评分与APACHE-Ⅳ和其他ICU预测模型在心脏手术后ICU患者中的效果,发现尽管SOFA评分对医院和ICU死亡率具有良好的区分能力,但APACHE-Ⅳ和SAPS-II的区分能力更佳[22],表明APACHE-Ⅳ(APSIII作为其组成部分)在预测重症患者死亡风险方面具有重要价值。因此,APSIII评分可能是TBAD患者短期死亡风险的有效预测因子。RDW是一个反映红细胞大小变异性的指标,已被证明是多种疾病的独立死亡风险预测因子。一项研究发现,RDW是腹膜透析患者全因死亡的预测因子[23]另一项研究表明,RDW在高风险胃肠手术患者的住院死亡率预测中同样具有良好的准确性[24]。此外,RDW也被发现与脑梗死患者的早期死亡率相[25],同时在急性心肌梗死患者的住院死亡率预测中也具有良好的预测价值[26],这些研究表明,慢性疾病、急性应激反应、心血管不良事件等均可能导致RDW的升高,此外,慢性炎症、营养不良或骨髓功能障碍同样与RDW的升高有关。而在TBAD患者中,这些因素可能导致患者的整体状况较差,从而增加死亡风险。因此,RDW也可作为TBAD患者短期死亡风险的有效预测因子。
       此外,在本研究中还发现,TCO2也可作为TBAD患者短期死亡风险的有效预测因子,但其在预测TBAD患者14 d内死亡风险的模型中表现为保护性因素。TCO2指的是血液中二氧化碳的总量,其包括溶解的二氧化碳、碳酸和碳酸氢盐。它是维持体内酸碱平衡的关键因素之一。正常的TCO2水平有助于维持稳定的血液pH值,这对于细胞功能和代谢过程至关重要。TCO2水平可以反映患者的代谢状态,例如代谢性酸中毒(如由于肾功能不全或糖尿病酮症酸中毒)可能导致TCO2水平降低。相反,正常或较高的TCO2水平可能表明没有严重的代谢紊乱。一项研究发现,血清TCO2浓度与脓毒症患者的28 d死亡率有关,当血清TCO2浓度低于20 mmol/L与死亡率呈现几乎线性的相关性,而当血清TCO2浓度高于20 mmol/L时,死亡率与TCO2浓度之间的这种关联不再存在,因此,在这项研究中,血清TCO2浓度是预测败血症患者预后的独立因素[27]。另一项研究探讨了脓毒症幸存者中血清TCO2水平与长期临床结果之间的关联,发现低TCO2组的患者有更高的全因死亡率、心肌梗死和终末期肾病风险[28]。同样,在TBAD患者身上,正常或稍高的TCO2水平可能反映了机体对疾病状态的适应性反应,维持了相对稳定的酸碱平衡。这种平衡状态可能有助于减少由于代谢紊乱引起的并发症,从而降低死亡风险。因此,TCO2也可能是TBAD患者短期死亡风险的有效预测因子。
       在这项研究中,我们开发并内部验证了TBAD 患者14 d内死亡风险的个体化预测列线图模型。我们找到了APSIII评分、TCO2、RDW这三个临床非常容易获取的变量来预测TBAD患者14 d内死亡风险。该模型在预测TBAD患者14 d内死亡风险方面表现良好。模型的内部验证显示出良好的区分能力和校准能力。此外,DCA表明该模型几乎对于全概率阈值范围的决策具有临床意义。我们构建的列线图模型提供了一个评估TBAD患者短期死亡风险的实用工具。然而,这一模型是基于欧美人群所构建的,同时缺乏外部验证,其有效性和准确性需要在更广泛的人群和不同的临床环境中进行验证。未来的研究应关注在TBAD患者中开发和验证综合多种临床指标和生物标志物的预测模型。在条件允许的情况下进行大规模的前瞻性队列研究,以进一步对模型进行验证。
       综上所述,本研究构建的列线图预测模型具有良好的区分度、校准能力和临床适用性,能够更好地帮助临床医生在急性期内更准确地评估TBAD患者的死亡风险,并据此制定更合适的治疗策略。
1、HAGAN%E2%80%83P%E2%80%83G%EF%BC%8CNIENABER%E2%80%83C%E2%80%83A%EF%BC%8CISSELBACHER%E2%80%83E%E2%80%83%0AM%EF%BC%8Cet%E2%80%83al%EF%BC%8EThe%E2%80%83%20International%E2%80%83Registry%E2%80%83of%E2%80%83Acute%E2%80%83Aortic%E2%80%83%0ADissection%EF%BC%88IRAD%EF%BC%89%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJAMA%EF%BC%8C2000%EF%BC%8C283%0A%EF%BC%887%EF%BC%89%EF%BC%9A897%EF%BC%8EHAGAN%E2%80%83P%E2%80%83G%EF%BC%8CNIENABER%E2%80%83C%E2%80%83A%EF%BC%8CISSELBACHER%E2%80%83E%E2%80%83%0AM%EF%BC%8Cet%E2%80%83al%EF%BC%8EThe%E2%80%83%20International%E2%80%83Registry%E2%80%83of%E2%80%83Acute%E2%80%83Aortic%E2%80%83%0ADissection%EF%BC%88IRAD%EF%BC%89%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJAMA%EF%BC%8C2000%EF%BC%8C283%0A%EF%BC%887%EF%BC%89%EF%BC%9A897%EF%BC%8E
2、ERBEL%E2%80%83R%EF%BC%8CABOYANS%E2%80%83V%EF%BC%8CBOILEAU%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8E2014%E2%80%83%0AESC%E2%80%83Guidelines%E2%80%83on%E2%80%83the%E2%80%83diagnosis%E2%80%83and%E2%80%83treatment%E2%80%83of%E2%80%83aortic%E2%80%83%0Adiseases%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEur%E2%80%83Heart%E2%80%83J%EF%BC%8C2014%EF%BC%8C35%EF%BC%8841%EF%BC%89%EF%BC%9A%0A2873%E2%80%932926%EF%BC%8EERBEL%E2%80%83R%EF%BC%8CABOYANS%E2%80%83V%EF%BC%8CBOILEAU%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8E2014%E2%80%83%0AESC%E2%80%83Guidelines%E2%80%83on%E2%80%83the%E2%80%83diagnosis%E2%80%83and%E2%80%83treatment%E2%80%83of%E2%80%83aortic%E2%80%83%0Adiseases%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEur%E2%80%83Heart%E2%80%83J%EF%BC%8C2014%EF%BC%8C35%EF%BC%8841%EF%BC%89%EF%BC%9A%0A2873%E2%80%932926%EF%BC%8E
3、HOWARD%E2%80%83D%E2%80%83P%EF%BC%8CBANERJEE%E2%80%83A%EF%BC%8CFAIRHEAD%E2%80%83J%E2%80%83F%EF%BC%8Cet%E2%80%83%0Aal%EF%BC%8EPopulation-based%E2%80%83study%E2%80%83of%E2%80%83incidence%E2%80%83and%E2%80%83outcome%E2%80%83%0Aof%E2%80%83%20acute%E2%80%83%20aortic%E2%80%83%20dissection%E2%80%83%20and%E2%80%83%20premorbid%E2%80%83%20risk%E2%80%83factor%E2%80%83%0Acontrol%EF%BC%9A10-year%E2%80%83%20results%E2%80%83from%E2%80%83the%E2%80%83Oxford%E2%80%83Vascular%E2%80%83%0AStudy%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECirculation%EF%BC%8C2013%EF%BC%8C127%EF%BC%8820%EF%BC%89%EF%BC%9A%0A2031%E2%80%932037%EF%BC%8EHOWARD%E2%80%83D%E2%80%83P%EF%BC%8CBANERJEE%E2%80%83A%EF%BC%8CFAIRHEAD%E2%80%83J%E2%80%83F%EF%BC%8Cet%E2%80%83%0Aal%EF%BC%8EPopulation-based%E2%80%83study%E2%80%83of%E2%80%83incidence%E2%80%83and%E2%80%83outcome%E2%80%83%0Aof%E2%80%83%20acute%E2%80%83%20aortic%E2%80%83%20dissection%E2%80%83%20and%E2%80%83%20premorbid%E2%80%83%20risk%E2%80%83factor%E2%80%83%0Acontrol%EF%BC%9A10-year%E2%80%83%20results%E2%80%83from%E2%80%83the%E2%80%83Oxford%E2%80%83Vascular%E2%80%83%0AStudy%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECirculation%EF%BC%8C2013%EF%BC%8C127%EF%BC%8820%EF%BC%89%EF%BC%9A%0A2031%E2%80%932037%EF%BC%8E
4、SUZUKI%E2%80%83T%EF%BC%8CEAGLE%E2%80%83K%E2%80%83A%EF%BC%8CBOSSONE%E2%80%83E%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AMedical%E2%80%83management%E2%80%83in%E2%80%83type%E2%80%83B%E2%80%83aortic%E2%80%83dissection%EF%BC%8E%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AAnn%E2%80%83Cardiothorac%E2%80%83Surg%EF%BC%8C2014%EF%BC%8C3%EF%BC%884%EF%BC%89%EF%BC%9A413%E2%80%93417%EF%BC%8ESUZUKI%E2%80%83T%EF%BC%8CEAGLE%E2%80%83K%E2%80%83A%EF%BC%8CBOSSONE%E2%80%83E%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AMedical%E2%80%83management%E2%80%83in%E2%80%83type%E2%80%83B%E2%80%83aortic%E2%80%83dissection%EF%BC%8E%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AAnn%E2%80%83Cardiothorac%E2%80%83Surg%EF%BC%8C2014%EF%BC%8C3%EF%BC%884%EF%BC%89%EF%BC%9A413%E2%80%93417%EF%BC%8E
5、MUNSHI%E2%80%83B%EF%BC%8CRITTER%E2%80%83J%E2%80%83C%EF%BC%8CDOYLE%E2%80%83B%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AManagement%E2%80%83of%E2%80%83acute%E2%80%83type%E2%80%83B%E2%80%83aortic%E2%80%83dissection%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AANZ%E2%80%83J%E2%80%83Surg%EF%BC%8C2020%EF%BC%8C90%EF%BC%8812%EF%BC%89%EF%BC%9A2425%E2%80%932433%EF%BC%8EMUNSHI%E2%80%83B%EF%BC%8CRITTER%E2%80%83J%E2%80%83C%EF%BC%8CDOYLE%E2%80%83B%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AManagement%E2%80%83of%E2%80%83acute%E2%80%83type%E2%80%83B%E2%80%83aortic%E2%80%83dissection%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AANZ%E2%80%83J%E2%80%83Surg%EF%BC%8C2020%EF%BC%8C90%EF%BC%8812%EF%BC%89%EF%BC%9A2425%E2%80%932433%EF%BC%8E
6、LUEBKE%E2%80%83T%EF%BC%8CBRUNKWALL%E2%80%83J%EF%BC%8ETy%20pe%E2%80%83%20B%E2%80%83%20ao%20rtic%E2%80%83%0Adissection%EF%BC%9AA%E2%80%83review%E2%80%83of%E2%80%83prognostic%E2%80%83factors%E2%80%83and%E2%80%83meta%02analysis%E2%80%83of%E2%80%83treatment%E2%80%83options%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAorta%EF%BC%8C2014%EF%BC%8C2%0A%EF%BC%886%EF%BC%89%EF%BC%9A265%E2%80%93278%EF%BC%8ELUEBKE%E2%80%83T%EF%BC%8CBRUNKWALL%E2%80%83J%EF%BC%8ETy%20pe%E2%80%83%20B%E2%80%83%20ao%20rtic%E2%80%83%0Adissection%EF%BC%9AA%E2%80%83review%E2%80%83of%E2%80%83prognostic%E2%80%83factors%E2%80%83and%E2%80%83meta%02analysis%E2%80%83of%E2%80%83treatment%E2%80%83options%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAorta%EF%BC%8C2014%EF%BC%8C2%0A%EF%BC%886%EF%BC%89%EF%BC%9A265%E2%80%93278%EF%BC%8E
7、NEWMAN%E2%80%83J%EF%BC%8CMATTIA%E2%80%83A%EF%BC%8CMATTIA%E2%80%83A%EF%BC%8EIndications%E2%80%83%0Afor%E2%80%83thoracic%E2%80%83EndoVascular%E2%80%83aortic%E2%80%83repair%EF%BC%88TEVAR%EF%BC%89%EF%BC%9A%0AA%E2%80%83brief%E2%80%83review%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Angiol%EF%BC%8C2018%EF%BC%8C27%EF%BC%884%EF%BC%89%EF%BC%9A%0A177%E2%80%93184%EF%BC%8ENEWMAN%E2%80%83J%EF%BC%8CMATTIA%E2%80%83A%EF%BC%8CMATTIA%E2%80%83A%EF%BC%8EIndications%E2%80%83%0Afor%E2%80%83thoracic%E2%80%83EndoVascular%E2%80%83aortic%E2%80%83repair%EF%BC%88TEVAR%EF%BC%89%EF%BC%9A%0AA%E2%80%83brief%E2%80%83review%EF%BC%BBJ%EF%BC%BD%EF%BC%8EInt%E2%80%83J%E2%80%83Angiol%EF%BC%8C2018%EF%BC%8C27%EF%BC%884%EF%BC%89%EF%BC%9A%0A177%E2%80%93184%EF%BC%8E
8、ZHANG%E2%80%83M%E2%80%83H%EF%BC%8CDU%E2%80%83X%EF%BC%8CGUO%E2%80%83W%EF%BC%8Cet%E2%80%83al%EF%BC%8EEarly%E2%80%83%20and%E2%80%83%0Amidterm%E2%80%83%20outcomes%E2%80%83%20of%E2%80%83thoracic%E2%80%83%20endovascular%E2%80%83%20aortic%E2%80%83%0Arepair%EF%BC%88TEVAR%EF%BC%89for%E2%80%83acute%E2%80%83and%E2%80%83chronic%E2%80%83complicated%E2%80%83%0Atype%E2%80%83B%E2%80%83aortic%E2%80%83dissection%EF%BC%BBJ%EF%BC%BD%EF%BC%8EMedicine%EF%BC%8C2017%EF%BC%8C96%0A%EF%BC%8828%EF%BC%89%EF%BC%9Ae7183%EF%BC%8EZHANG%E2%80%83M%E2%80%83H%EF%BC%8CDU%E2%80%83X%EF%BC%8CGUO%E2%80%83W%EF%BC%8Cet%E2%80%83al%EF%BC%8EEarly%E2%80%83%20and%E2%80%83%0Amidterm%E2%80%83%20outcomes%E2%80%83%20of%E2%80%83thoracic%E2%80%83%20endovascular%E2%80%83%20aortic%E2%80%83%0Arepair%EF%BC%88TEVAR%EF%BC%89for%E2%80%83acute%E2%80%83and%E2%80%83chronic%E2%80%83complicated%E2%80%83%0Atype%E2%80%83B%E2%80%83aortic%E2%80%83dissection%EF%BC%BBJ%EF%BC%BD%EF%BC%8EMedicine%EF%BC%8C2017%EF%BC%8C96%0A%EF%BC%8828%EF%BC%89%EF%BC%9Ae7183%EF%BC%8E
9、DESAI%E2%80%83N%E2%80%83D%EF%BC%8CGOTTRET%E2%80%83J%E2%80%83P%EF%BC%8CSZETO%E2%80%83W%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AImpact%E2%80%83of%E2%80%83timing%E2%80%83on%E2%80%83major%E2%80%83complications%E2%80%83after%E2%80%83thoracic%E2%80%83%0Aendovascular%E2%80%83%20aortic%E2%80%83%20repair%E2%80%83for%E2%80%83%20acute%E2%80%83type%E2%80%83%20B%E2%80%83%20aortic%E2%80%83%0Adissection%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Thorac%E2%80%83Cardiovasc%E2%80%83Surg%EF%BC%8C2015%EF%BC%8C%0A149%EF%BC%882%EF%BC%89%EF%BC%9AS151-S156%EF%BC%8EDESAI%E2%80%83N%E2%80%83D%EF%BC%8CGOTTRET%E2%80%83J%E2%80%83P%EF%BC%8CSZETO%E2%80%83W%E2%80%83Y%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AImpact%E2%80%83of%E2%80%83timing%E2%80%83on%E2%80%83major%E2%80%83complications%E2%80%83after%E2%80%83thoracic%E2%80%83%0Aendovascular%E2%80%83%20aortic%E2%80%83%20repair%E2%80%83for%E2%80%83%20acute%E2%80%83type%E2%80%83%20B%E2%80%83%20aortic%E2%80%83%0Adissection%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Thorac%E2%80%83Cardiovasc%E2%80%83Surg%EF%BC%8C2015%EF%BC%8C%0A149%EF%BC%882%EF%BC%89%EF%BC%9AS151-S156%EF%BC%8E
10、%E2%80%83%20TORRENT%E2%80%83D%E2%80%83J%EF%BC%8CMCFARLAND%E2%80%83G%E2%80%83E%EF%BC%8CWANG%E2%80%83G%EF%BC%8Cet%E2%80%83%0Aal%EF%BC%8ETiming%E2%80%83of%E2%80%83thoracic%E2%80%83endovascular%E2%80%83aortic%E2%80%83%20repair%E2%80%83for%E2%80%83%0Auncomplicated%E2%80%83acute%E2%80%83type%E2%80%83B%E2%80%83aortic%E2%80%83dissection%E2%80%83and%E2%80%83the%E2%80%83%0Aassociation%E2%80%83with%E2%80%83complications%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Vasc%E2%80%83Surg%EF%BC%8C%0A2021%EF%BC%8C73%EF%BC%883%EF%BC%89%EF%BC%9A826%E2%80%93835%EF%BC%8E%E2%80%83%20TORRENT%E2%80%83D%E2%80%83J%EF%BC%8CMCFARLAND%E2%80%83G%E2%80%83E%EF%BC%8CWANG%E2%80%83G%EF%BC%8Cet%E2%80%83%0Aal%EF%BC%8ETiming%E2%80%83of%E2%80%83thoracic%E2%80%83endovascular%E2%80%83aortic%E2%80%83%20repair%E2%80%83for%E2%80%83%0Auncomplicated%E2%80%83acute%E2%80%83type%E2%80%83B%E2%80%83aortic%E2%80%83dissection%E2%80%83and%E2%80%83the%E2%80%83%0Aassociation%E2%80%83with%E2%80%83complications%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Vasc%E2%80%83Surg%EF%BC%8C%0A2021%EF%BC%8C73%EF%BC%883%EF%BC%89%EF%BC%9A826%E2%80%93835%EF%BC%8E
11、%E2%80%83%20ZILBER%E2%80%83Z%E2%80%83A%EF%BC%8CBODDU%E2%80%83A%EF%BC%8CMALAISRIE%E2%80%83S%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ANoninvasive%E2%80%83morphologic%E2%80%83and%E2%80%83hemodynamic%E2%80%83evaluation%E2%80%83%0Aof%E2%80%83type%E2%80%83B%E2%80%83aortic%E2%80%83dissection%EF%BC%9Astate%E2%80%83of%E2%80%83the%E2%80%83art%E2%80%83and%E2%80%83future%E2%80%83%0Aperspectives%EF%BC%BBJ%EF%BC%BD%EF%BC%8ERadiol%E2%80%83Cardiothorac%E2%80%83Imaging%EF%BC%8C%0A2021%EF%BC%8C3%EF%BC%883%EF%BC%89%EF%BC%9Ae200456%EF%BC%8E%E2%80%83%20ZILBER%E2%80%83Z%E2%80%83A%EF%BC%8CBODDU%E2%80%83A%EF%BC%8CMALAISRIE%E2%80%83S%E2%80%83C%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ANoninvasive%E2%80%83morphologic%E2%80%83and%E2%80%83hemodynamic%E2%80%83evaluation%E2%80%83%0Aof%E2%80%83type%E2%80%83B%E2%80%83aortic%E2%80%83dissection%EF%BC%9Astate%E2%80%83of%E2%80%83the%E2%80%83art%E2%80%83and%E2%80%83future%E2%80%83%0Aperspectives%EF%BC%BBJ%EF%BC%BD%EF%BC%8ERadiol%E2%80%83Cardiothorac%E2%80%83Imaging%EF%BC%8C%0A2021%EF%BC%8C3%EF%BC%883%EF%BC%89%EF%BC%9Ae200456%EF%BC%8E
12、杨帅,于红静,何家欣,等.ICU患者再喂养综合征风险预测模型的研究进展[J].现代医院,2024,24(2):317-319,324.杨帅,于红静,何家欣,等.ICU患者再喂养综合征风险预测模型的研究进展[J].现代医院,2024,24(2):317-319,324.
13、谢恋,卢慧英,王瑞瑜,等.老年吸入性肺炎的危险因素分析及风险预测模型构建[J].广州医药,2022,53(2):12-16,22.谢恋,卢慧英,王瑞瑜,等.老年吸入性肺炎的危险因素分析及风险预测模型构建[J].广州医药,2022,53(2):12-16,22.
14、杨正霞,王和勇,贺施琪,等.基于随机森林算法建立甲状腺功能减退患病风险预测模型[J].广州医药,2023,54(7):16–24.杨正霞,王和勇,贺施琪,等.基于随机森林算法建立甲状腺功能减退患病风险预测模型[J].广州医药,2023,54(7):16–24.
15、陈志丹,陈德杰.甲状腺癌术后复发相关危险因素分析及复发预测模型构建[J].东南大学学报(医学版),2015,34(1):92–95.陈志丹,陈德杰.甲状腺癌术后复发相关危险因素分析及复发预测模型构建[J].东南大学学报(医学版),2015,34(1):92–95.
16、WU%E2%80%83H%EF%BC%8CLIAO%E2%80%83B%EF%BC%8CJI%E2%80%83T%EF%BC%8Cet%E2%80%83al%EF%BC%8EA%E2%80%83nomogram%E2%80%83for%E2%80%83predicting%E2%80%83%0Ain-hospital%E2%80%83overall%E2%80%83survival%E2%80%83of%E2%80%83hypertriglyceridemia%02induced%E2%80%83severe%E2%80%83acute%E2%80%83pancreatitis%EF%BC%9AA%E2%80%83single%E2%80%83center%EF%BC%8C%0Across-sectional%E2%80%83study%EF%BC%BBJ%EF%BC%BD%EF%BC%8EHeliyon%EF%BC%8C2023%EF%BC%8C10%0A%EF%BC%881%EF%BC%89%EF%BC%9Ae23454%EF%BC%8EWU%E2%80%83H%EF%BC%8CLIAO%E2%80%83B%EF%BC%8CJI%E2%80%83T%EF%BC%8Cet%E2%80%83al%EF%BC%8EA%E2%80%83nomogram%E2%80%83for%E2%80%83predicting%E2%80%83%0Ain-hospital%E2%80%83overall%E2%80%83survival%E2%80%83of%E2%80%83hypertriglyceridemia%02induced%E2%80%83severe%E2%80%83acute%E2%80%83pancreatitis%EF%BC%9AA%E2%80%83single%E2%80%83center%EF%BC%8C%0Across-sectional%E2%80%83study%EF%BC%BBJ%EF%BC%BD%EF%BC%8EHeliyon%EF%BC%8C2023%EF%BC%8C10%0A%EF%BC%881%EF%BC%89%EF%BC%9Ae23454%EF%BC%8E
17、XU%E2%80%83L%EF%BC%8CDU%E2%80%83S%EF%BC%8CJIN%E2%80%83L%EF%BC%8EPredictive%E2%80%83model%E2%80%83for%E2%80%83pulmonary%E2%80%83%0Aembolism%E2%80%83in%E2%80%83pregnant%E2%80%83and%E2%80%83postpartum%E2%80%83women%EF%BC%9AA%E2%80%8310-%0Ayear%E2%80%83retrospective%E2%80%83study%EF%BC%BBJ%EF%BC%BD%EF%BC%8EClin%E2%80%83Appl%E2%80%83%20Thromb%E2%80%83%0AHemost%EF%BC%8C2023%EF%BC%8C29%EF%BC%9A10760296231209930%EF%BC%8EXU%E2%80%83L%EF%BC%8CDU%E2%80%83S%EF%BC%8CJIN%E2%80%83L%EF%BC%8EPredictive%E2%80%83model%E2%80%83for%E2%80%83pulmonary%E2%80%83%0Aembolism%E2%80%83in%E2%80%83pregnant%E2%80%83and%E2%80%83postpartum%E2%80%83women%EF%BC%9AA%E2%80%8310-%0Ayear%E2%80%83retrospective%E2%80%83study%EF%BC%BBJ%EF%BC%BD%EF%BC%8EClin%E2%80%83Appl%E2%80%83%20Thromb%E2%80%83%0AHemost%EF%BC%8C2023%EF%BC%8C29%EF%BC%9A10760296231209930%EF%BC%8E
18、HOWARD%E2%80%83C%EF%BC%8CSHERIDAN%E2%80%83J%EF%BC%8CPICCA%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ATEVAR%E2%80%83for%E2%80%83%20complicated%E2%80%83%20anduncomplicated%E2%80%83type%E2%80%83%20B%E2%80%83%0Aaortic%E2%80%83dissection-Systematic%E2%80%83review%E2%80%83and%E2%80%83meta-analysis%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Card%E2%80%83Surg%EF%BC%8C2021%EF%BC%8C36%EF%BC%8810%EF%BC%89%EF%BC%9A3820-3830%EF%BC%8EHOWARD%E2%80%83C%EF%BC%8CSHERIDAN%E2%80%83J%EF%BC%8CPICCA%E2%80%83L%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0ATEVAR%E2%80%83for%E2%80%83%20complicated%E2%80%83%20anduncomplicated%E2%80%83type%E2%80%83%20B%E2%80%83%0Aaortic%E2%80%83dissection-Systematic%E2%80%83review%E2%80%83and%E2%80%83meta-analysis%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EJ%E2%80%83Card%E2%80%83Surg%EF%BC%8C2021%EF%BC%8C36%EF%BC%8810%EF%BC%89%EF%BC%9A3820-3830%EF%BC%8E
19、LASICA%E2%80%83R%E2%80%83M%EF%BC%8CPERUNICIC%E2%80%83J%E2%80%83P%EF%BC%8CPOPOVIC%E2%80%83D%E2%80%83R%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EEarly%E2%80%83and%E2%80%83late%E2%80%83mortality%E2%80%83%20predictors%E2%80%83in%E2%80%83%20patients%E2%80%83%0Awith%E2%80%83acute%E2%80%83aortic%E2%80%83dissection%E2%80%83type%E2%80%83B%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECardiol%E2%80%83Res%E2%80%83%0APract%EF%BC%8C2022%EF%BC%882022%EF%BC%89%EF%BC%9A7869356%EF%BC%8ELASICA%E2%80%83R%E2%80%83M%EF%BC%8CPERUNICIC%E2%80%83J%E2%80%83P%EF%BC%8CPOPOVIC%E2%80%83D%E2%80%83R%EF%BC%8C%0Aet%E2%80%83al%EF%BC%8EEarly%E2%80%83and%E2%80%83late%E2%80%83mortality%E2%80%83%20predictors%E2%80%83in%E2%80%83%20patients%E2%80%83%0Awith%E2%80%83acute%E2%80%83aortic%E2%80%83dissection%E2%80%83type%E2%80%83B%EF%BC%BBJ%EF%BC%BD%EF%BC%8ECardiol%E2%80%83Res%E2%80%83%0APract%EF%BC%8C2022%EF%BC%882022%EF%BC%89%EF%BC%9A7869356%EF%BC%8E
20、%E2%80%83%20QUINTANA%E2%80%83J%E2%80%83M%EF%BC%8CESTEBAN%E2%80%83C%EF%BC%8CUNZURRUNZAGA%E2%80%83%0AA%EF%BC%8Cet%E2%80%83al%EF%BC%8EPredictive%E2%80%83%20score%E2%80%83for%E2%80%83mortality%E2%80%83in%E2%80%83%20patients%E2%80%83%0Awith%E2%80%83COPD%E2%80%83exacerbations%E2%80%83attending%E2%80%83hospital%E2%80%83emergency%E2%80%83%0Adepartments%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBMC%E2%80%83Med%EF%BC%8C2014%EF%BC%8812%EF%BC%89%EF%BC%9A66%EF%BC%8E%E2%80%83%20QUINTANA%E2%80%83J%E2%80%83M%EF%BC%8CESTEBAN%E2%80%83C%EF%BC%8CUNZURRUNZAGA%E2%80%83%0AA%EF%BC%8Cet%E2%80%83al%EF%BC%8EPredictive%E2%80%83%20score%E2%80%83for%E2%80%83mortality%E2%80%83in%E2%80%83%20patients%E2%80%83%0Awith%E2%80%83COPD%E2%80%83exacerbations%E2%80%83attending%E2%80%83hospital%E2%80%83emergency%E2%80%83%0Adepartments%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBMC%E2%80%83Med%EF%BC%8C2014%EF%BC%8812%EF%BC%89%EF%BC%9A66%EF%BC%8E
21、PAN%E2%80%83L%E2%80%83N%EF%BC%8CPAN%E2%80%83S%E2%80%83A%EF%BC%8CLEI%E2%80%83B%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8EDevelopment%E2%80%83%0Aof%E2%80%83%20a%E2%80%83%20novel%E2%80%83%20nomogram%E2%80%83incorporating%E2%80%83%20red%E2%80%83%20blood%E2%80%83%20cell%E2%80%83%0Adistribution%E2%80%83width-albumin%E2%80%83%20ratio%E2%80%83for%E2%80%83the%E2%80%83prediction%E2%80%83of%E2%80%83%0A30-day%E2%80%83mortality%E2%80%83in%E2%80%83acute%E2%80%83pancreatitis%E2%80%83patients%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEmerg%E2%80%83Med%E2%80%83Int%EF%BC%8C2022%EF%BC%882022%EF%BC%89%EF%BC%9A1573931%EF%BC%8EPAN%E2%80%83L%E2%80%83N%EF%BC%8CPAN%E2%80%83S%E2%80%83A%EF%BC%8CLEI%E2%80%83B%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8EDevelopment%E2%80%83%0Aof%E2%80%83%20a%E2%80%83%20novel%E2%80%83%20nomogram%E2%80%83incorporating%E2%80%83%20red%E2%80%83%20blood%E2%80%83%20cell%E2%80%83%0Adistribution%E2%80%83width-albumin%E2%80%83%20ratio%E2%80%83for%E2%80%83the%E2%80%83prediction%E2%80%83of%E2%80%83%0A30-day%E2%80%83mortality%E2%80%83in%E2%80%83acute%E2%80%83pancreatitis%E2%80%83patients%EF%BC%BBJ%EF%BC%BD%EF%BC%8EEmerg%E2%80%83Med%E2%80%83Int%EF%BC%8C2022%EF%BC%882022%EF%BC%89%EF%BC%9A1573931%EF%BC%8E
22、%E2%80%83%20SCHOE%E2%80%83A%EF%BC%8CBAKHSHI-RAIEZ%E2%80%83F%EF%BC%8Cde%E2%80%83KEIZER%E2%80%83N%EF%BC%8Cet%E2%80%83%0Aal%EF%BC%8EMortality%E2%80%83prediction%E2%80%83by%E2%80%83SOFA%E2%80%83score%E2%80%83in%E2%80%83ICU-patients%E2%80%83%0Aafter%E2%80%83cardiac%E2%80%83surgery%EF%BC%9Bcomparison%E2%80%83%20with%E2%80%83traditional%E2%80%83%0Aprognostic-models%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBMC%E2%80%83Anesthesiol%EF%BC%8C2020%EF%BC%8C%0A20%EF%BC%881%EF%BC%89%EF%BC%9A65%EF%BC%8E%E2%80%83%20SCHOE%E2%80%83A%EF%BC%8CBAKHSHI-RAIEZ%E2%80%83F%EF%BC%8Cde%E2%80%83KEIZER%E2%80%83N%EF%BC%8Cet%E2%80%83%0Aal%EF%BC%8EMortality%E2%80%83prediction%E2%80%83by%E2%80%83SOFA%E2%80%83score%E2%80%83in%E2%80%83ICU-patients%E2%80%83%0Aafter%E2%80%83cardiac%E2%80%83surgery%EF%BC%9Bcomparison%E2%80%83%20with%E2%80%83traditional%E2%80%83%0Aprognostic-models%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBMC%E2%80%83Anesthesiol%EF%BC%8C2020%EF%BC%8C%0A20%EF%BC%881%EF%BC%89%EF%BC%9A65%EF%BC%8E
23、SUN%E2%80%83I%E2%80%83O%EF%BC%8CCHUNG%E2%80%83B%E2%80%83H%EF%BC%8CYOON%E2%80%83H%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8EClinical%E2%80%83%0Asignificance%E2%80%83of%E2%80%83%20red%E2%80%83blood%E2%80%83cell%E2%80%83distribution%E2%80%83width%E2%80%83in%E2%80%83the%E2%80%83%0Aprediction%E2%80%83of%E2%80%83mortality%E2%80%83in%E2%80%83patients%E2%80%83on%E2%80%83peritoneal%E2%80%83dialysis%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EKidney%E2%80%83Res%E2%80%83Clin%E2%80%83Pract%EF%BC%8C2016%EF%BC%8C35%EF%BC%882%EF%BC%89%EF%BC%9A%0A114%E2%80%93118%EF%BC%8ESUN%E2%80%83I%E2%80%83O%EF%BC%8CCHUNG%E2%80%83B%E2%80%83H%EF%BC%8CYOON%E2%80%83H%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8EClinical%E2%80%83%0Asignificance%E2%80%83of%E2%80%83%20red%E2%80%83blood%E2%80%83cell%E2%80%83distribution%E2%80%83width%E2%80%83in%E2%80%83the%E2%80%83%0Aprediction%E2%80%83of%E2%80%83mortality%E2%80%83in%E2%80%83patients%E2%80%83on%E2%80%83peritoneal%E2%80%83dialysis%0A%EF%BC%BBJ%EF%BC%BD%EF%BC%8EKidney%E2%80%83Res%E2%80%83Clin%E2%80%83Pract%EF%BC%8C2016%EF%BC%8C35%EF%BC%882%EF%BC%89%EF%BC%9A%0A114%E2%80%93118%EF%BC%8E
24、PLUTA%E2%80%83M%EF%BC%8CKLOCEK%E2%80%83T%EF%BC%8CKRZYCH%E2%80%83%C5%81%E2%80%83%20J%EF%BC%8ETrafno%C5%9B%C4%87%0Adiagnostyczna%E2%80%83wska%C5%BAnika%E2%80%83zmienno%C5%9Bci%E2%80%83%20rozmia%20ru%E2%80%83%0Aerytrocyt%C3%B3w%E2%80%83w%E2%80%83przewidywaniu%E2%80%83zgonu%E2%80%83szpitalnego%E2%80%83u%E2%80%83chorych%E2%80%83%0Apoddawanych%E2%80%83operacjom%E2%80%83przewodu%E2%80%83pokarmowego%E2%80%83du%C5%BCego%E2%80%83%0Aryzyka%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAnestezjol%E2%80%83Intensive%E2%80%83Ther%EF%BC%8C2018%EF%BC%8C50%0A%EF%BC%884%EF%BC%89%EF%BC%9A277%E2%80%93282%EF%BC%8EPLUTA%E2%80%83M%EF%BC%8CKLOCEK%E2%80%83T%EF%BC%8CKRZYCH%E2%80%83%C5%81%E2%80%83%20J%EF%BC%8ETrafno%C5%9B%C4%87%0Adiagnostyczna%E2%80%83wska%C5%BAnika%E2%80%83zmienno%C5%9Bci%E2%80%83%20rozmia%20ru%E2%80%83%0Aerytrocyt%C3%B3w%E2%80%83w%E2%80%83przewidywaniu%E2%80%83zgonu%E2%80%83szpitalnego%E2%80%83u%E2%80%83chorych%E2%80%83%0Apoddawanych%E2%80%83operacjom%E2%80%83przewodu%E2%80%83pokarmowego%E2%80%83du%C5%BCego%E2%80%83%0Aryzyka%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAnestezjol%E2%80%83Intensive%E2%80%83Ther%EF%BC%8C2018%EF%BC%8C50%0A%EF%BC%884%EF%BC%89%EF%BC%9A277%E2%80%93282%EF%BC%8E
25、LORENTE%E2%80%83L%EF%BC%8CMART%C3%8DN%E2%80%83M%E2%80%83M%EF%BC%8CABREU-GONZ%C3%81LEZ%E2%80%83%0AP%EF%BC%8Cet%E2%80%83al%EF%BC%8EEarly%E2%80%83mortality%E2%80%83of%E2%80%83brain%E2%80%83infarction%E2%80%83patients%E2%80%83%0Aand%E2%80%83red%E2%80%83blood%E2%80%83cell%E2%80%83distribution%E2%80%83width%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBrain%E2%80%83%0ASci%EF%BC%8C2020%EF%BC%8C10%EF%BC%884%EF%BC%89%EF%BC%9A196%EF%BC%8ELORENTE%E2%80%83L%EF%BC%8CMART%C3%8DN%E2%80%83M%E2%80%83M%EF%BC%8CABREU-GONZ%C3%81LEZ%E2%80%83%0AP%EF%BC%8Cet%E2%80%83al%EF%BC%8EEarly%E2%80%83mortality%E2%80%83of%E2%80%83brain%E2%80%83infarction%E2%80%83patients%E2%80%83%0Aand%E2%80%83red%E2%80%83blood%E2%80%83cell%E2%80%83distribution%E2%80%83width%EF%BC%BBJ%EF%BC%BD%EF%BC%8EBrain%E2%80%83%0ASci%EF%BC%8C2020%EF%BC%8C10%EF%BC%884%EF%BC%89%EF%BC%9A196%EF%BC%8E
26、SANGOI%E2%80%83M%EF%BC%8CGUARDA%E2%80%83N%EF%BC%8CR%C3%96DEL%E2%80%83A%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0APrognostic%E2%80%83value%E2%80%83of%E2%80%83%20red%E2%80%83blood%E2%80%83cell%E2%80%83distribution%E2%80%83width%E2%80%83in%E2%80%83%0Aprediction%E2%80%83of%E2%80%83in-hospital%E2%80%83mortality%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83acute%E2%80%83%0Amyocardial%E2%80%83infarction%EF%BC%BBJ%EF%BC%BD%EF%BC%8EClin%E2%80%83Lab%EF%BC%8C2014%EF%BC%8C60%0A%EF%BC%888%EF%BC%89%EF%BC%9A1351-1356%EF%BC%8ESANGOI%E2%80%83M%EF%BC%8CGUARDA%E2%80%83N%EF%BC%8CR%C3%96DEL%E2%80%83A%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0APrognostic%E2%80%83value%E2%80%83of%E2%80%83%20red%E2%80%83blood%E2%80%83cell%E2%80%83distribution%E2%80%83width%E2%80%83in%E2%80%83%0Aprediction%E2%80%83of%E2%80%83in-hospital%E2%80%83mortality%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83acute%E2%80%83%0Amyocardial%E2%80%83infarction%EF%BC%BBJ%EF%BC%BD%EF%BC%8EClin%E2%80%83Lab%EF%BC%8C2014%EF%BC%8C60%0A%EF%BC%888%EF%BC%89%EF%BC%9A1351-1356%EF%BC%8E
27、KIM%E2%80%83J%E2%80%83H%EF%BC%8CJANG%E2%80%83D-H%EF%BC%8CJO%E2%80%83Y%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8ESerum%E2%80%83%0Atotal%E2%80%83carbon%E2%80%83dioxide%E2%80%83as%E2%80%83a%E2%80%83prognostic%E2%80%83factor%E2%80%83for%E2%80%8328-day%E2%80%83%0Amortality%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83sepsis%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAm%E2%80%83%20J%E2%80%83Emerg%E2%80%83%0AMed%EF%BC%8C2021%EF%BC%8844%EF%BC%89%EF%BC%9A277-283%EF%BC%8EKIM%E2%80%83J%E2%80%83H%EF%BC%8CJANG%E2%80%83D-H%EF%BC%8CJO%E2%80%83Y%E2%80%83H%EF%BC%8Cet%E2%80%83al%EF%BC%8ESerum%E2%80%83%0Atotal%E2%80%83carbon%E2%80%83dioxide%E2%80%83as%E2%80%83a%E2%80%83prognostic%E2%80%83factor%E2%80%83for%E2%80%8328-day%E2%80%83%0Amortality%E2%80%83in%E2%80%83patients%E2%80%83with%E2%80%83sepsis%EF%BC%BBJ%EF%BC%BD%EF%BC%8EAm%E2%80%83%20J%E2%80%83Emerg%E2%80%83%0AMed%EF%BC%8C2021%EF%BC%8844%EF%BC%89%EF%BC%9A277-283%EF%BC%8E
28、YANG%E2%80%83C%E2%80%83H%EF%BC%8CCHEN%E2%80%83Y%E2%80%83A%EF%BC%8CBIN%E2%80%83P%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AAssociations%E2%80%83of%E2%80%83the%E2%80%83erum%E2%80%83total%E2%80%83carbon%E2%80%83dioxide%E2%80%83level%E2%80%83with%E2%80%83%0Along-term%E2%80%83clinical%E2%80%83outcomes%E2%80%83in%E2%80%83sepsis%E2%80%83survivors%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AInfect%E2%80%83Dis%E2%80%83Ther%EF%BC%8C2023%EF%BC%8C12%EF%BC%882%EF%BC%89%EF%BC%9A687%E2%80%93701%EF%BC%8EYANG%E2%80%83C%E2%80%83H%EF%BC%8CCHEN%E2%80%83Y%E2%80%83A%EF%BC%8CBIN%E2%80%83P%E2%80%83J%EF%BC%8Cet%E2%80%83al%EF%BC%8E%0AAssociations%E2%80%83of%E2%80%83the%E2%80%83erum%E2%80%83total%E2%80%83carbon%E2%80%83dioxide%E2%80%83level%E2%80%83with%E2%80%83%0Along-term%E2%80%83clinical%E2%80%83outcomes%E2%80%83in%E2%80%83sepsis%E2%80%83survivors%EF%BC%BBJ%EF%BC%BD%EF%BC%8E%0AInfect%E2%80%83Dis%E2%80%83Ther%EF%BC%8C2023%EF%BC%8C12%EF%BC%882%EF%BC%89%EF%BC%9A687%E2%80%93701%EF%BC%8E
上一篇
下一篇
出版者信息








《广州医药》公众号
目录